Interview: Aussie biotech on the cusp of big breakthrough
ASX-listed biotech Mesoblast is spoken about a lot on Fear and Greed due to its extremely volatile share price. This is largely tied to some big medical breakthroughs they've been working on for a long time.
Founder Silviu Itescu discusses the exhaustive and expensive process behind getting criti…
Sunday feature: The Australian biotech on the verge of a major breakthrough
Guest: Mesoblast founder Silviu Itescu
Original air date: March 9, 2022
ASX-listed biotech Mesoblast is spoken about a lot on Fear and Greed due to its extremely volatile share price. This is largely tied to some big medical breakthroughs they've been working on for a long time.
Founder Silviu …
Sunday feature: This Aussie company's share price is up 900% this year
Guest: Mesoblast founder Silviu Itescu
Original air date: March 9, 2022
ASX-listed biotech Mesoblast is spoken about a lot on Fear and Greed due to its extremely volatile share price. This is largely tied to some big medical breakthroughs they've been working on for a long time.
Founder Silv…
NYC Congestion Pricing, Stem Cell Therapy
Watch Carol and Tim LIVE every day on YouTube: http://bit.ly/3vTiACF.Journalist and author Henry Grabar on NYC’s Congestion Pricing and how this could help the Democratic Party. Dr. Silviu Itescu, CEO at Mesoblast, on MESO stock soaring after FDA stem cell therapy approval. And we Drive to the Clo…
Business Plans and Science Projects
Do you have a real relationship or just a non-binding letter of intent?
(00:21) Nick Sciple and Mary Long discuss:
- The S&P’s turnaround and inflation’s slow month-over-month decline.
- A stock pop from a nuclear reactor company that doesn’t have a working nuclear reactor.
- Pricing for Dis…
From the helm: Mesoblast (ASX:MSB), Director, Silviu Itescu
In this episode of From the Helm, Grady sits down with Mesoblast Director Silviu Itescu, to unpack the recent approval and launch of their Ryoncil drug for children, their outlook for the next 12 months in capturing the adult market, and their extensive pipeline of further products.
An Off-the-Shelf Cell Therapy to Calm Cytokine Storms
Small molecule drugs and monoclonal antibodies often fall short at addressing severe inflammatory and immune‑mediated diseases. Mesoblast has spent more than 15 years industrializing mesenchymal stromal cell therapies to treat these conditions. In late 2024, it won U.S. Food and Drug Administratio…
Business Plans and Science Projects
Do you have a real relationship or just a non-binding letter of intent? (00:21) Nick Sciple and Mary Long discuss: - The S&P’s turnaround and inflation’s slow month-over-month decline. - A stock pop from a nuclear reactor company that doesn’t have a working nuclear reactor. - Pricing for Dis…
מנוע חיפוש PODCAST
אתה יכול להשתמש באתר שלנו כדי לחפש3,832,095פודקאסטים ופודקאסטים196,973,230לפי אנשים, מקומות או נושאים.
השקעה בידע מניבה את התשואה הטובה ביותר, ולכן אני מאזין לפודקאסטים.
‐ Benjamin "Llamacorn" Franklin
